神经内分泌肿瘤发病的代谢危险因素

摘要/Abstract

中图分类号:

R736

张婕, 毕宇芳. 神经内分泌肿瘤发病的代谢危险因素[J]. 内科理论与实践, 2023, 18(04): 251-255.

ZHANG Jie, BI Yufang. Metabolic risk factors for development of neuroendocrine tumors[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 251-255.

参考文献49

[1]	Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States[J]. JAMA Oncol, 2017, 3(10): 1335-1342. doi:10.1001/jamaoncol.2017.0589pmid:28448665
[2]	Muscogiuri G, Altieri B, Albertelli M, et al. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective[J]. Endocrine, 2020, 69(2): 441-450. doi:10.1007/s12020-020-02331-3pmid:32468269
[3]	Ruggeri RM, Benevento E, De Cicco F, et al. Neuroendocrine neoplasms in the context of inherited tumor syndromes[J]. J Endocrinol Invest, 2023, 46(2): 213-234. doi:10.1007/s40618-022-01905-4
[4]	Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(7): 844-860. doi:S0923-7534(20)36394-8pmid:32272208
[5]	Oronsky B, Ma PC, Morgensztern D, et al. Nothing but NET: a review of neuroendocrine tumors and carcinomas[J]. Neoplasia, 2017, 19(12): 991-1002. doi:S1476-5586(17)30347-0pmid:29091800
[6]	Díez M, Teulé A, Salazar R. Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment[J]. Ann Gastroenterol, 2013, 26(1): 29-36.
[7]	Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States[J]. J Clin Oncol, 2008, 26(18): 3063-3072. doi:10.1200/JCO.2007.15.4377 URL
[8]	Thorson A, Biorck G, Bjorkman G, et al. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome[J]. Am Heart J, 1954, 47(5): 795-817. pmid:13158264
[9]	Riihimäki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors[J]. Int J Cancer, 2016, 139(12): 2679-2686. doi:10.1002/ijc.30400pmid:27553864
[10]	Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours[J]. Lancet Oncol, 2008, 9(1): 61-72. doi:10.1016/S1470-2045(07)70410-2pmid:18177818
[11]	Hassan MM, Phan A, Li D, et al. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study[J]. Int J Cancer, 2008, 123(4): 867-873. doi:10.1002/ijc.23529pmid:18491401
[12]	Hassan MM, Phan A, Li D, et al. Family history of cancer and associated risk of developing neuroendocrine tumor[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(4): 959-965. doi:10.1158/1055-9965.EPI-07-0750 URL
[13]	Halfdanarson TR, Bamlet WR, McWilliams RR, et al. Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study[J]. Pancreas, 2014, 43(8): 1219-1222. doi:10.1097/MPA.0000000000000234 URL
[14]	Cigrovski Berković M, Catela Ivković T, Marout J, et al. Interleukin 1β gene single-nucleotide polymorphisms and susceptibility to pancreatic neuroendocrine tumors[J]. DNA Cell Biol, 2012, 31(4): 531-536. doi:10.1089/dna.2011.1317pmid:21988351
[15]	Kaerlev L, Teglbjaerg PS, Sabroe S, et al. Occupational risk factors for small bowel carcinoid tumor: a European population-based case-control study[J]. J Occup Environ Med, 2002, 44(6): 516-522. pmid:12085477
[16]	Capurso G, Falconi M, Panzuto F, et al. Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients[J]. Am J Gastroenterol, 2009, 104(12): 3034-3041. doi:10.1038/ajg.2009.466pmid:19690522
[17]	Karakaxas D, Gazouli M, Coker A, et al. Genetic polymorphisms of inflammatory response gene TNF-α and its influence on sporadic pancreatic neuroendocrine tumors predisposition risk[J]. Med Oncol, 2014, 31(10): 241. doi:10.1007/s12032-014-0241-zpmid:25213764
[18]	Berković M, Cacev T, Zjacić Rotkvić V, et al. TNF-alpha promoter single nucleotide polymorphisms in gastro-enteropancreatic neuroendocrine tumors[J]. Neuroendocrin-ology, 2006, 84(5): 346-352.
[19]	Burnik FS, Yalçin S. NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors[J]. Chemotherapy, 2009, 55(5): 381-385. doi:10.1159/000237744 URL
[20]	Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors[J]. Cancer, 2003, 97(4): 934-959. doi:10.1002/cncr.11105pmid:12569593
[21]	Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?[J]. Curr Oncol Rep, 2021, 23(4): 43. doi:10.1007/s11912-021-01029-7pmid:33719003
[22]	Ohtani N, Yoshimoto S, Hara E. Obesity and cancer: a gut microbial connection[J]. Cancer Res, 2014, 74(7): 1885-1889. doi:10.1158/0008-5472.CAN-13-3501pmid:24638983
[23]	Tsuei J, Chau T, Mills D, et al. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer[J]. Exp Biol Med (Maywood), 2014, 239(11): 1489-1504. doi:10.1177/1535370214538743pmid:24951470
[24]	Herrera-Martínez AD, Pedraza-Arevalo S, L-López F, et al. Type 2 diabetes in neuroendocrine tumors: are biguanides and statins part of the solution?[J]. J Clin Endocrinol Metab, 2019, 104(1): 57-73. doi:10.1210/jc.2018-01455pmid:30265346
[25]	Santos AP, Santos AC, Castro C, et al. Visceral obesity and metabolic syndrome are associated with well-differentiated gastroenteropancreatic neuroendocrine tumors[J]. Cancers (Basel), 2018, 10(9): 293. doi:10.3390/cancers10090293 URL
[26]	Pyo JH, Hong SN, Min BH, et al. Evaluation of the risk factors associated with rectal neuroendocrine tumors: a big data analytic study from a health screening center[J]. J Gastroenterol, 2016, 51(12): 1112-1121. pmid:27025841
[27]	Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr relat cancer[J]. Endocr Relat Cancer, 2009, 16(4): 1103-1123. doi:10.1677/ERC-09-0087 URL
[28]	Gallo M, Ruggeri RM, Muscogiuri G, et al. Diabetes and pancreatic neuroendocrine tumours: which interplays, if any?[J]. Cancer Treat Rev, 2018, 67: 1-9. doi:S0305-7372(18)30057-4pmid:29746922
[29]	Mottin CC, Cruz RP, Gomes Thomé G, et al. Carcinoid tumors and morbid obesity[J]. Obes Surg, 2009, 19(2): 247-249. doi:10.1007/s11695-008-9541-8pmid:18506551
[30]	Al-Harbi O, Shakir M, Al-Brahim N. Gastric carcinoid and obesity: association or coincidence? Report of two cases and literature review[J]. Case Rep Gastrointest Med, 2013, 2013: 848075.
[31]	Perryman S, Kaltenbach T, Eisenberg D. Preoperative finding of gastric neuroendocrine tumor (gastric carcinoid) in a patient evaluated for bariatric surgery[J]. Surg Obes Relat Dis, 2011, 7(5): e18-e20. doi:10.1016/j.soard.2010.11.005 URL
[32]	Cross AJ, Hollenbeck AR, Park Y. A large prospective study of risk factors for adenocarcinomas and malignant carcinoid tumors of the small intestine[J]. Cancer Causes Control, 2013, 24(9): 1737-1746. doi:10.1007/s10552-013-0251-8 URL
[33]	Zhan HX, Cong L, Zhao YP, et al. Risk factors for the occurrence of insulinoma: a case-control study[J]. Hepatobiliary Pancreat Dis Int, 2013, 12(3): 324-328. doi:10.1016/S1499-3872(13)60051-X URL
[34]	Vitale G, Dicitore A, Barrea L, et al. From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?[J]. Rev Endocr Metab Disord, 2021, 22(3): 511-525. doi:10.1007/s11154-020-09589-y
[35]	Leoncini E, Carioli G, La Vecchia C, et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis[J]. Ann Oncol, 2016, 27(1): 68-81. doi:10.1093/annonc/mdv505pmid:26487581
[36]	Barrea L, Altieri B, Muscogiuri G, et al. Impact of nutritional status on gastroenteropancreatic neuroendocrine tumors (GEP-NET) aggressiveness[J]. Nutrients, 2018, 10(12): 1854. doi:10.3390/nu10121854 URL
[37]	Bostan H, Duger H, Akhanli P, et al. Cushing’s syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine tumor of unknown primary origin: a case report and literature review[J]. Hormones (Athens), 2022, 21(1): 147-154. doi:10.1007/s42000-021-00316-z
[38]	Zainal A, Akinsola O, Rajamani K. Cushing syndrome secondary to primary neuroendocrine lung carcinoma[J]. Case Rep Endocrinol, 2019, 2019: 1989260.
[39]	Wu Y, Yue L, Li J, et al. Cushing’s syndrome secondary to typical pulmonary carcinoid with mutation in BCOR gene: a case report[J]. Medicin (Baltimore), 2017, 96(34): e7870.
[40]	Kamp K, Alwani RA, Korpershoek E, et al. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors[J]. Eur J Endocrinol, 2016, 174(3): 271-280. doi:10.1530/EJE-15-0968pmid:26643855
[41]	Jyotsna VP, Malik E, Birla S, et al. Novel MEN 1 gene findings in rare sporadic insulinoma—a case control study[J]. BMC Endocr Disord, 2015, 15: 44. doi:10.1186/s12902-015-0041-2pmid:26307114
[42]	Maric A, Katalinic D, Belovari M, et al. Insulinoma and extreme obesity in a patient with MEN1 syndrome[J]. Acta Gastroenterol Belg, 2010, 73(2): 296-297. pmid:20690576
[43]	Lee JM, Shin J, Kim S, et al. Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neuroendocrine tumors (ROHHADNET) syndrome[J]. Biomed Res Int, 2018, 2018: 1250721.
[44]	Raccosta L, Fontana R, Maggioni D, et al. The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils[J]. J Exp Med, 2013, 210(9): 1711-1728. doi:10.1084/jem.20130440 URL
[45]	Wu AH, Yu MC, Mack TM. Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma[J]. Int J Cancer, 1997, 70(5): 512-517. pmid:9052748
[46]	Cross AJ, Leitzmann MF, Subar AF, et al. A prospective study of meat and fat intake in relation to small intestinal cancer[J]. Cancer Res, 2008, 68(22): 9274-9279. doi:10.1158/0008-5472.CAN-08-2015pmid:19010900
[47]	Barrea L, Muscogiuri G, Modica R, et al. Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors[J]. Front Endocrinol (Lausanne), 2021, 12: 649496. doi:10.3389/fendo.2021.649496 URL
[48]	Feola T, Puliani G, Sesti F, et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study[J]. J Endocrinol Invest, 2022, 45(4): 849-857. doi:10.1007/s40618-021-01715-0pmid:35040099
[49]	Good ML, Malekzadeh P, Ruff SM, et al. Surgical resection of pheochromocytomas and paragangliomas is associated with lower cholesterol levels[J]. World J Surg, 2020, 44(2): 552-560. doi:10.1007/s00268-019-05175-9pmid:31531722

神经内分泌肿瘤发病的代谢危险因素

Metabolic risk factors for development of neuroendocrine tumors

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献49

相关文章15

编辑推荐

Metrics

本文评价

[1]	詹崇文, 沈奇伟, 邵怡凯, 许博, 花荣, 姚琪远.三孔法腹腔镜胃袖状切除术治疗肥胖症的疗效分析[J]. 外科理论与实践, 2023, 28(05): 463-468.
[2]	顾燕云, 周薇薇, 王卫庆, 宁光.原发性色素沉着结节性肾上腺皮质病[J]. 内科理论与实践, 2023, 18(04): 230-233.
[3]	张翠, 王卫庆.异位促肾上腺皮质激素综合征[J]. 内科理论与实践, 2023, 18(04): 242-246.
[4]	张婕, 陆洁莉.非胰岛细胞肿瘤所致的低血糖临床诊治进展[J]. 内科理论与实践, 2023, 18(04): 256-260.
[5]	史玉玲, 陈文娟.银屑病共病的现状及诊治[J]. 诊断学理论与实践, 2023, 22(03): 221-229.
[6]	黄先觉, 姚琪远.微创手术助推肥胖与代谢性疾病的外科治疗[J]. 外科理论与实践, 2023, 28(03): 215-219.
[7]	吴春晓, 顾凯, 庞怡, 王春芳, 施亮, 向詠梅, 龚杨明, 窦剑明, 施燕, 付晨.2002—2016年上海市小肠癌发病、死亡和生存分析[J]. 外科理论与实践, 2023, 28(03): 240-248.
[8]	韩序, 王文权, 楼文晖, 刘亮.免疫检查点抑制剂治疗胃肠胰神经内分泌肿瘤的进展[J]. 外科理论与实践, 2023, 28(03): 267-272.
[9]	张梦潇, 韦晓, 张少红, 陈国芳, 刘超.生长分化因子15：减重治疗的新靶点[J]. 内科理论与实践, 2023, 18(02): 128-130.
[10]	张音, 沈宏华, 许轶明, 任蕾, 李骏, 吴顺军, 凌小楠.肌少症合并腹型肥胖对住院老年人肌力及躯体功能的影响[J]. 内科理论与实践, 2023, 18(02): 76-82.
[11]	孔韦奇, 何俊, 杨成广, 刘微薇, 徐英杰.嗜铬细胞瘤合并甲状腺乳头状癌（附1例报告）[J]. 外科理论与实践, 2023, 28(02): 162-165.
[12]	张梦潇, 孙烁烁, 韦晓, 张少红, 陈国芳, 刘超.生酮饮食诱导db/db小鼠肝脏脂肪沉积[J]. 内科理论与实践, 2023, 18(01): 56-63.
[13]	王泽洲, 郑莹.1990年至2020年间全球及我国肺癌的发病流行趋势及防控措施[J]. 诊断学理论与实践, 2023, 22(01): 1-7.
[14]	梁晨, 于佳佳, 唐神结.世界卫生组织《全球结核病报告2022》解读[J]. 诊断学理论与实践, 2023, 22(01): 21-30.
[15]	秦雪, 郭华, 张云云, 崔小川.C1q肿瘤坏死因子相关蛋白3与代谢相关疾病的研究进展[J]. 内科理论与实践, 2022, 17(06): 482-485.